Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Scholar Rock shares rose sharply in pre-market trading after the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy. The drug is the first and only muscle-targeted treatment approved for children and adults with SMA, creating a significant commercial and clinical milestone for the company.